Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 27, 2015 11:03 PM ET

Biotechnology

Company Overview of LoneStar Heart, Inc.

Company Overview

LoneStar Heart, Inc., a biomedical company, develops cardiac restorative therapies for patients with heart failure. It develops a portfolio of device and drug based programs for congestive heart failure. The company develops Algisyl LVR, a self-gelling implantable biopolymer that is implanted in the heart for preventing or reversing the progression of advanced heart failure in patients who have an enlarged left ventricle as a result of a myocardial infarct, mitral valve regurgitation, ischemia, arrhythmias, and other disorders; and Isoxazoles, small molecule drugs for the treatment of heart failure. The company also develops cell reprogramming cardiac fibroblasts for the regeneration of card...

26051 Merit Circle

Suite 102

Laguna Hills, CA 92653

United States

Founded in 2010

Phone:

949-348-1188

Fax:

949-348-1866

Key Executives for LoneStar Heart, Inc.

President, Chief Operating Officer and Director
Founder and Executive Chairman
Age: 65
Founder, Chief Scientific Advisor and Director
Founder
Age: 75
Vice President of Clinical & Regulatory Affairs
Age: 52
Compensation as of Fiscal Year 2015.

LoneStar Heart, Inc. Key Developments

LoneStar Heart Receives European Approval to Market its Algisyl-LVR(R) Hydrogel Implant for the Treatment of Advanced Heart Failure

LoneStar Heart, Inc. announced that it received the CE Mark (Conformite Europeene) for its Algisyl-LVR(R) hydrogel implant, the company's lead product for the treatment of advanced heart failure (HF). Classified in Europe and in the U.S. as a medical device, Algisyl-LVR is intended to reverse HF progression in people who have an enlarged left ventricle. Surgically injected directly into the heart muscle, the hydrogel acts immediately as an internal scaffold that does not undergo long-term degradation and increases cardiac output. The CE Mark indicates a product's compliance with European Union legislation and that it can be sold throughout the European Economic Area. Six-month patient outcome studies of Algisyl-LVR will be presented at the annual meeting of the American Heart Association (AHA), November 15-19, 2014 in Chicago. The AUGMENT-HF randomized clinical trial is being conducted at 14 centers in Italy, Germany, Romania, Australia, and The Netherlands to determine if the product is superior to standard medical therapy in the management of patients with a dilated and weakened left ventricle and significantly deteriorated cardiac function.

LoneStar Heart Presents at 13th Annual BIO Investor Forum, Oct-07-2014 01:30 PM

LoneStar Heart Presents at 13th Annual BIO Investor Forum, Oct-07-2014 01:30 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.

LoneStar Heart Closes Patient Enrollment in Clinical Trial of Algisyl-LVR for Advanced Heart Failure

LoneStar Heart has completed the patient recruitment Phase of its AUGMENT-HF controlled randomized trial of its lead product Algisyl-LVR hydrogel implant for the treatment of advanced heart failure (HF). The AUGMENT-HF clinical trial is being carried out at 14 centers in Italy, Germany, Romania, Australia, and The Netherlands and its six-month outcomes are expected to be reported by the end of 2014. The trial is designed to determine if the product is superior to standard medical therapy in the management of patients with a dilated and weakened left ventricle and significantly deteriorated cardiac function. Interim results of the trial showed left ventricle augmentation of the failing heart after implantation with Algisyl-LVR can be performed safely in patients with advanced heart failure and provides functional improvement in their health status.

Similar Private Companies By Industry

Company Name Region
D-finitive Technologies, Inc. United States
AgBiome, LLC United States
Alopexx Enterprises, LLC United States
Target Discovery, Inc. United States
China For-Gen Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LoneStar Heart, Inc., please visit www.lonestarheartinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.